Please Wait
Applying Filters...
menu
    • menu
    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    Data Compilation
    #PharmaFlow

    Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

    Stock Recap
    #PipelineProspector

    Menu

    UNII-8A1O1M485B

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 893Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Name of the Firm Written Confirmation No. Product Name Issue Date Valid Till Address of the Firm
    04/06/2025 BDR Lifesciences
    India
    		 M/s BDR lifesciences Pvt Ltd WC-0340 Imatinib Mesylate IP 2022-09-30 2025-04-14 R.S No: 578, Near Effluent Channel, at & Post: Luna, Taluka: Padra, District: Vadodara-391440, India
    04/06/2025 BDR Lifesciences
    India
    		 M/s BDR Lifesciences Pvt Ltd WC-340n Imatinib Mesylate IP 2022-09-30 2025-04-14 RS No: 578, Near Effluent Channel, at & Post: Luna, Taluka: Padra, District: Vadodara-391440, India